Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series
العنوان: | Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series |
---|---|
المؤلفون: | Shouyin Di, Siyu Chen, Caiying Yue, Shao-Hua Zhou, Junqiang Liu, Boshi Fan, Weian Song, Jiahua Zhao, Taiqian Gong, Hai Dong |
المصدر: | Thoracic Cancer Thoracic Cancer, Vol 11, Iss 4, Pp 1061-1067 (2020) |
بيانات النشر: | John Wiley & Sons Australia, Ltd, 2020. |
سنة النشر: | 2020 |
مصطلحات موضوعية: | 0301 basic medicine, Pulmonary and Respiratory Medicine, Adult, Male, medicine.medical_specialty, Lung Neoplasms, salvage surgery, medicine.medical_treatment, Adenocarcinoma of Lung, lcsh:RC254-282, survival, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Molecular Targeted Therapy, Stage (cooking), Lung cancer, Pathological, Aged, Retrospective Studies, Salvage Therapy, Lung, business.industry, Postoperative complication, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, targeted therapy, Prognosis, Surgery, Survival Rate, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Adenocarcinoma, Salvage surgery, Original Article, Female, business, Non‐small cell lung cancer, Follow-Up Studies |
الوصف: | Background Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literature. Methods A retrospective analysis of patients who underwent salvage surgery in our center between January 2016 and June 2019 for advanced NSCLC after targeted therapy was performed. Results A total number of nine patients were identified, including five males and four females, with a median age of 56 years (range, 40-65 years), all diagnosed with lung adenocarcinoma stage IIIa-IVb. All patients had received targeted therapy according to individual positive mutation of driver gene(s). Salvage surgery was performed for tumor recurrence or residual tumor after a duration of 2-46 months of targeted therapy. A negative surgical margin was achieved in all cases. Postoperative complication rate was 11.1% (1/9). All patients were alive at the time of this analysis and two patients had disease progression. After a median follow-up of 17 months (range: 5-44 months), the median event-free survival and postoperative survival was 14 months (range: 2-44 months) and 17 months (range: 5-44 months) respectively. Conclusions Salvage surgery may be a feasible and promising therapeutic option for tumor recurrence or residual tumor in advanced NSCLC in selective patients after targeted therapy. Key points Salvage surgery is feasible in selected patients with advanced NSCLC and provides promising survival outcomes after targeted therapy failure. Salvage surgery provides precise molecular and pathological information which is most important for subsequent therapy. |
اللغة: | English |
تدمد: | 1759-7714 1759-7706 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a249be10feaf6a70e5aab664c9041661 http://europepmc.org/articles/PMC7113042 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi.dedup.....a249be10feaf6a70e5aab664c9041661 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 17597714 17597706 |
---|